BTG PLC (BTG.L)

BTG.L on London Stock Exchange

549.50GBp
3:37pm IST
Price Change (% chg)

-2.00p (-0.36%)
Prev Close
551.50p
Open
552.00p
Day's High
552.50p
Day's Low
546.00p
Volume
349,582
Avg. Vol
577,712
52-wk High
624.40p
52-wk Low
323.10p

BTG.L

Chart for BTG.L

About

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are... (more)

Overall

Beta: 0.53
Market Cap (Mil.): £1,994.15
Shares Outstanding (Mil.): 361.59
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 90.62 33.12 33.26
EPS (TTM): 0.06 -- --
ROI: 3.91 19.69 18.95
ROE: 4.49 20.39 19.72
Search Stocks

BRIEF-BTG sees year revenue around top end of guidance range

LONDON, April 3 - BTG plc update for the year ended 31 March 2014:

03 Apr 2014

BRIEF-BTG trading in line, reiterates full-year guidance

Jan 29 - BTG PLC : * Trading overall during the period and in the year to date has been in line

29 Jan 2014

BTG's varicose vein treatment wins U.S. approval

LONDON - British pharmaceutical firm BTG said U.S. regulators had approved its varicose vein treatment that uses an injectable foam to dissolve the veins as an alternative to surgical removal.

26 Nov 2013

UPDATE 1-BTG's varicose vein treatment wins US approval

* Injectable foam treatment approved after long development

26 Nov 2013

BTG's groundbreaking varicose veins treatment wins US approval

LONDON, Nov 26 - British pharmaceutical firm BTG said U.S. regulators had approved its groundbreaking varicose veins treatment that uses an injectable foam to dissolve the veins as an alternative to stripping.

26 Nov 2013

Earnings vs. Estimates

Search Stocks